Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Mln 8237
2. Mln-8237
3. Mln8237
1. 1028486-01-2
2. Mln8237
3. Mln-8237
4. Mln 8237
5. Mln8237 (alisertib)
6. 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic Acid
7. Alisertib [usan]
8. 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic Acid
9. Chembl483158
10. T66es73m18
11. Alisertib (usan)
12. 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-benzo[c]pyrimido-[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic Acid
13. 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic Acid
14. Benzoic Acid, 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido(5,4-d)(2)benzazepin-2-yl)amino)-2-methoxy-
15. Alisertib [usan:inn]
16. Unii-t66es73m18
17. Mln8237,alisertib
18. Kinome_3770
19. Alisertib [inn]
20. Alisertib; Mln8237
21. Alisertib (mln8237)
22. Mln8237 - Alisertib
23. Alisertib [who-dd]
24. Mls006011041
25. Schembl855823
26. Gtpl7790
27. Dtxsid30145539
28. Ex-a024
29. Min8237
30. Chebi:125628
31. Hms3654e08
32. Hms3673i07
33. Hms3743e17
34. Amy24201
35. Bcp01823
36. Bdbm50277545
37. Mfcd16621243
38. Nsc759677
39. Nsc799329
40. S1133
41. Zinc40939534
42. Akos015924647
43. Bcp9000956
44. Ccg-264832
45. Cs-0106
46. Db05220
47. Mln 8237 (contain 10% Dmso)
48. Nsc-759677
49. Nsc-799329
50. Sb16658
51. Ncgc00263271-01
52. Ncgc00263271-02
53. Ncgc00263271-10
54. 4-(9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-2-methoxybenzoic Acid
55. Ac-25236
56. As-17005
57. Hy-10971
58. Smr004702834
59. Ft-0672433
60. Sw219771-1
61. D10085
62. J-514220
63. Brd-k75295174-001-03-5
64. Q15633917
65. 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-benzo[c]pyrimido-[4,5-e]azepin-2-yl)amino)-2-methoxy Mln 8237 (contain 10% Dmso)
66. 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido(5,4-d)(2)benzazepin-2-yl)amino)-2-methoxy-benzoic Acid
67. 4-(9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-benzo[e]pyrimido[5,4-c]azepin-2-ylamino)-2-methoxybenzoic Acid
68. 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl) -5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic Acid
69. A5b
| Molecular Weight | 518.9 g/mol |
|---|---|
| Molecular Formula | C27H20ClFN4O4 |
| XLogP3 | 5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 6 |
| Exact Mass | 518.1157110 g/mol |
| Monoisotopic Mass | 518.1157110 g/mol |
| Topological Polar Surface Area | 106 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 836 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of various forms of cancer.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Alisertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Alisertib, including repackagers and relabelers. The FDA regulates Alisertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Alisertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Alisertib supplier is an individual or a company that provides Alisertib active pharmaceutical ingredient (API) or Alisertib finished formulations upon request. The Alisertib suppliers may include Alisertib API manufacturers, exporters, distributors and traders.
Alisertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Alisertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Alisertib GMP manufacturer or Alisertib GMP API supplier for your needs.
A Alisertib CoA (Certificate of Analysis) is a formal document that attests to Alisertib's compliance with Alisertib specifications and serves as a tool for batch-level quality control.
Alisertib CoA mostly includes findings from lab analyses of a specific batch. For each Alisertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Alisertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Alisertib EP), Alisertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Alisertib USP).
LOOKING FOR A SUPPLIER?
